This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. SERA, XGN, BDSX, MDXH, OPGN, BNR, ENZ, ACON, BGLC, and NTRAShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Sera Prognostics (SERA), Exagen (XGN), Biodesix (BDSX), MDxHealth (MDXH), OpGen (OPGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), Aclarion (ACON), BioNexus Gene Lab (BGLC), and Natera (NTRA). Miragen Therapeutics vs. Sera Prognostics Exagen Biodesix MDxHealth OpGen Burning Rock Biotech Enzo Biochem Aclarion BioNexus Gene Lab Natera Sera Prognostics (NASDAQ:SERA) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Is SERA or MGEN more profitable? Sera Prognostics has a net margin of 0.00% compared to Miragen Therapeutics' net margin of -1,393.50%. Sera Prognostics' return on equity of -51.73% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sera PrognosticsN/A -51.73% -36.94% Miragen Therapeutics -1,393.50%-141.66%-88.74% Which has preferable earnings & valuation, SERA or MGEN? Sera Prognostics has higher earnings, but lower revenue than Miragen Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$77K1,638.63-$36.24M-$0.99-3.38Miragen Therapeutics$4.46M11.84-$41.87M-$20.09-0.67 Do insiders and institutionals hold more shares of SERA or MGEN? 54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SERA or MGEN? Miragen Therapeutics received 257 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformSera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Miragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% Which has more volatility & risk, SERA or MGEN? Sera Prognostics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Do analysts prefer SERA or MGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SERA or MGEN? In the previous week, Sera Prognostics had 2 more articles in the media than Miragen Therapeutics. MarketBeat recorded 2 mentions for Sera Prognostics and 0 mentions for Miragen Therapeutics. Sera Prognostics' average media sentiment score of 1.67 beat Miragen Therapeutics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media. Company Overall Sentiment Sera Prognostics Very Positive Miragen Therapeutics Neutral SummarySera Prognostics beats Miragen Therapeutics on 12 of the 17 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.80M$2.86B$5.42B$7.71BDividend YieldN/A31.34%5.44%4.33%P/E Ratio-1.2713.4722.2518.33Price / Sales11.84195.85397.52106.90Price / CashN/A57.5638.2034.62Price / Book1.994.746.834.25Net Income-$41.87M-$22.21M$3.21B$247.64M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$13.51-1.8%N/A-3.4%$52.80M$4.46M-1.2745Gap UpHigh Trading VolumeSERASera Prognostics0.7134 of 5 stars$3.48+2.7%N/A-65.7%$128.96M$77,000.00-3.46120News CoveragePositive NewsXGNExagen4.3981 of 5 stars$4.49flat$7.50+67.0%+317.5%$80.36M$55.64M-4.78220BDSXBiodesix3.3632 of 5 stars$0.51+1.8%$2.95+479.6%-61.3%$74.30M$71.32M-1.31220News CoverageMDXHMDxHealth2.7897 of 5 stars$1.56-2.8%$6.50+318.0%-29.8%$73.53M$90.05M-1.02300OPGNOpGenN/A$4.15-0.5%N/A-20.1%$34.68M$2.67M0.00100BNRBurning Rock Biotech0.4908 of 5 stars$2.85+1.8%N/A-65.8%$29.20M$515.82M-0.951,390Gap UpENZEnzo Biochem0.9659 of 5 stars$0.33-14.8%N/A-70.5%$17.03M$29.09M0.00520Analyst ForecastGap DownHigh Trading VolumeACONAclarion1.6726 of 5 stars$8.20+3.3%$11,758.50+143,383.8%-99.7%$4.80M$45,724.000.007Gap DownBGLCBioNexus Gene Lab0.2628 of 5 stars$2.63-1.7%N/A-50.3%$4.72M$9.26M0.0030Gap DownNTRANatera2.9594 of 5 stars$145.29+2.2%$175.76+21.0%+63.2%$19.64B$1.70B-82.563,020Insider TradeNews CoveragePositive News Related Companies and Tools Related Companies Sera Prognostics Alternatives Exagen Alternatives Biodesix Alternatives MDxHealth Alternatives OpGen Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives Aclarion Alternatives BioNexus Gene Lab Alternatives Natera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGEN Stock Free MGEN Stock Alerts